Open AccessP829: A PHASE III RANDOMIZED CLINICAL TRIAL COMPARING SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) WITH REFERENCE ECULIZUMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Author(s) -
Jang J. H.,
Demichelis Gomez R.,
Bumbea H.,
Nogaieva L.,
Wong L. L. L.,
Lim S. M.,
Park J.,
Kim Y.,
Cho S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846200.39589.36
Subject(s) - eculizumab , paroxysmal nocturnal hemoglobinuria , medicine , hemoglobinuria , gastroenterology , confidence interval , pharmacokinetics , randomized controlled trial , clinical endpoint , anemia , antibody , complement system , immunology